When does Takhzyro (lanadelumab) lose exclusivity in the UK?
The information provided here does not include Takhzyro’s UK exclusivity dates (for example, the end of any SPC, patent term, or data exclusivity period). Without those specific documents or dates, it’s not possible to state when Takhzyro loses exclusivity in the UK.
What “loss of exclusivity” could mean in the UK (and why the date can differ)
In UK medicines policy, “exclusivity” is usually driven by one or more of these timelines:
- Patent expiry (including any patent term extensions).
- Supplementary Protection Certificate (SPC) expiry, if granted.
- Regulatory data exclusivity and market exclusivity periods, which can delay marketing authorisations for competitors even after patent/SPC expiry.
Because each mechanism can end on a different date, the “first generic/biosimilar able to launch” date can differ from the “first authorisation able to be granted” date.
What I need to give you the exact UK date
If you share either:
- the product strength/formulation (Takhzyro is typically discussed as a specific strength and pack), and
- the source you’re using (e.g., a UK regulatory listing page, a specific patent/SPC number, or a link),
I can map the relevant exclusivity mechanism(s) to the end date and tell you when exclusivity ends in the UK.
Quick way to look up the date yourself (if you want)
To find the exact end date in the UK, check:
- UK SPC registers for lanadelumab (Takhzyro) to see whether an SPC exists and when it expires.
- Patent registers for the key lanadelumab patents used to support market exclusivity.
- UK regulatory exclusivity data in the medicine’s record (commonly via listings that summarise exclusivity/launch barriers).
If you meant “generic/biosimilar launch”
For a biologic like lanadelumab, “loss of exclusivity” often matters most for when another company can market a competing product. That typically aligns with the latest relevant protection ending (usually SPC/patent, and sometimes regulatory exclusivity), but the exact timing depends on how the competitor’s application is structured.
Sources: None provided in the prompt.